Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy

Journal of Urology

Volumn 156, Issue 1, 1996, Pages 137-143

  Lerner, Seth E ^a,b   Blute, Michael L ^a   Bergstralh, Erik J ^a   Bostwick, David G ^a   Eickholt, Jeffery T ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

prostatectomy; prostatic neoplasms; risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; TUMOR VOLUME;

EID: 0029977061     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65967-6     Document Type: Article

References (32)

1. Jewett, H. J., Bridge, R. W., Gray, G. F., Jr. and Shelley, W. M.: The palpable nodule of prostate cancer. Results 15 years after radical excision. J.A.M.A., 203: 403, 1968.
2. Morton, R. A., Steiner, M. S. and Walsh, P. C.: Cancer control following anatomical radical prostatectomy: an interim report. J. Urol., 145: 1197, 1991.
3. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstrahl, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., part 2, 152: 1850, 1994.
4. Culp, O. S.: Radical perineal prostatectomy: its past, present and possible future. J. Urol., 98: 618, 1968.
5. Jewett, H. J., Eggleston, J. C. and Yawn, D. H.: Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J. Urol., 107: 1034, 1972.
6. Benson, R. C., Jr., Tomera, K. M., Zincke, H., Fleming, T. R. and Utz, D. C.: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J. Urol., 131: 1103, 1984.
7. Blute, M. L., Nativ, O., Zincke, H., Farrow, G. M., Therneau, T. and Lieber, M. M.: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J. Urol., 142: 1262, 1989.
8. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
9. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
10. Morgan, W. R., Zincke, H., Rainwater, L. M., Myers, R. P. and Klee, G. G.: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). J. Urol., 145: 319, 1991.
11. Zincke, H., Blute, M. L., Fallen, M. J. and Farrow, G. M.: Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J. Urol., 146: 1053, 1991.
12. Gleason, D. F. and the Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, pp. 171-187, 1977.
13. Montie, J. E.: 1992 staging system for prostate cancer. Sem. Urol., 11: 10, 1993.
14. Winkler, H. Z., Rainwater, L. M., Myers, R. P., Farrow, G. M., Therneau, T. M., Zincke, H. and Leiber, M. M.: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin. Proc., 63: 103, 1988.
15. Kaplan, E. L. and Meier, P.: Non-parametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
16. Cox, D. R.: Regression models and life-tables. J. Roy. Stat. Soc. B, 34: 187, 1972.
17. McNeal, J. E.: Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Path., 23: 258, 1992.
18. Stamey, T. A., McNeal, J. E., Freiha, F. S. and Redwine, E.: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol., 139: 1235, 1988.
19. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
20. Epstein, J. I., Carmichael, M., Partin, A. W. and Walsh, P. C.: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J. Urol., 149: 1478, 1993.
21. Palken, M., Cobb, O. E., Warren, B. H. and Hoak, D. C.: Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J. Urol., 143: 1155, 1990.
22. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
23. Ruckle, H., Oesterling, J. E. and Zincke, H.: Relationship of high pre-prostatectomy prostate-specific antigen (PSA) levels to postoperative PSA levels and outcome in prostate cancer (PC). J. Urol., part 2, 151: 340A, abstract 450, 1994.
24. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zincke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
25. Catalona, W. J. and Smith, D. S.: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., part 2, 152: 1837, 1994.
26. Gleason, D. F., Mellinger, G. T. and the Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58, 1974.
27. Zincke, H.: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology, suppl., 33: 27, 1989.
28. Nativ, O., Winkler, H. Z., Raz, Y., Therneau, T. M., Farrow, G. M., Myers, R. P., Zincke, H. and Lieber, M. M.: Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin. Proc., 64: 911, 1989.
29. Montgomery, B. T., Nativ, O., Blute, M. L., Farrow, G. M., Myers, R. P., Zincke, H., Therneau, T. M. and Lieber, M. M.: Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch. Surg., 125: 327, 1990.
30. Carmichael, M. J., Veltri, R. W., Partin, A. W., Miller, M. C., Walsh, P. C. and Epstein, J. I.: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J. Urol., part 2, 153: 1015, 1995.
31. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
32. Cheng, W. S., Frydenberg, M., Bergstralh, E. J., Larson-Keller, J. J. and Zincke, H.: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology, 42: 283, 1993.